dc.contributor.author |
Murugesan, Sankaranarayanan |
|
dc.date.accessioned |
2023-12-11T10:48:29Z |
|
dc.date.available |
2023-12-11T10:48:29Z |
|
dc.date.issued |
2021-01 |
|
dc.identifier.uri |
https://www.future-science.com/doi/10.4155/fmc-2020-0257 |
|
dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13346 |
|
dc.description.abstract |
Reverse transcriptase and integrase are key enzymes that play a pivotal role in HIV-1 viral maturation and replication. Reverse transcriptase consists of two active sites: RNA-dependent DNA polymerase and RNase H. The catalytic domains of integrase and RNase H share striking similarity, comprising two aspartates and one glutamate residue, also known as the catalytic DDE triad, and a Mg2+ pair. The simultaneous inhibition of reverse transcriptase and integrase can be a rational drug discovery approach for combating the emerging drug resistance problem. In the present review, the dual inhibition of RNase H and integrase is systematically discussed, including rationality of design, journey of development, advancement and future perspective |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Future Science Group |
en_US |
dc.subject |
Pharmacy |
en_US |
dc.subject |
Dual inhibition |
en_US |
dc.subject |
Reverse transcriptase (RT) |
en_US |
dc.subject |
Integrase |
en_US |
dc.subject |
Molecular hybridization |
en_US |
dc.subject |
Resistancereverse transcriptase |
en_US |
dc.title |
Search for new therapeutics against HIV-1 via dual inhibition of RNase H and integrase: current status and future challenges |
en_US |
dc.type |
Article |
en_US |